Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Drug Safety
|
June 3, 2021
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, et al.
Revista Portuguesa De Pneumologia
|
February 23, 2007
[Pericardioperitoneal shunt in the treatment of pericardial effusions in neoplasic patients]
Nuno Cortesão, Ana Figueiredo, Fernando Barata, et al.
Acta Medica Portuguesa
|
December 1, 2009
[Cost of cancer care in Portugal]
António Araújo, Fernando Barata, Sérgio Barroso, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
António Araújo, Nuno Tavares, Ana Luísa Faria, et al.
Cancer Investigation
|
March 7, 2009
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer
António M F Arúajo, Jose C Mendez, Ana L Coelho, et al.
Journal of the National Cancer Institute
|
August 22, 2002
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
Johan Vansteenkiste, Robert Pirker, Bartomeu Massuti, et al.
Cancer Treatment and Research Communications
|
June 15, 2023
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Gabriela Fernandes, Ana Rodrigues, Cláudia Matos, et al.
The Lancet. Oncology
|
September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
Antonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
Alberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Drug Safety
|
June 3, 2021
Monitoring and Managing Lorlatinib Adverse Events in the Portuguese Clinical Setting: A Position Paper
Fernando Barata, Carlos Aguiar, Tiago Reis Marques, et al.
Revista Portuguesa De Pneumologia
|
February 23, 2007
[Pericardioperitoneal shunt in the treatment of pericardial effusions in neoplasic patients]
Nuno Cortesão, Ana Figueiredo, Fernando Barata, et al.
Acta Medica Portuguesa
|
December 1, 2009
[Cost of cancer care in Portugal]
António Araújo, Fernando Barata, Sérgio Barroso, et al.
Current Oncology (Toronto, Ont.)
|
February 24, 2023
Evaluation of Current Antiemetic Therapy Response in Patients Undergoing MEC or HEC Regimens in Portugal
António Araújo, Nuno Tavares, Ana Luísa Faria, et al.
Cancer Investigation
|
March 7, 2009
Phase II study of celecoxib with cisplatin plus etoposide in extensive-stage small cell lung cancer
António M F Arúajo, Jose C Mendez, Ana L Coelho, et al.
Journal of the National Cancer Institute
|
August 22, 2002
Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy
Johan Vansteenkiste, Robert Pirker, Bartomeu Massuti, et al.
Cancer Treatment and Research Communications
|
June 15, 2023
Liquid biopsy in the management of advanced lung cancer: Implementation and practical aspects
Gabriela Fernandes, Ana Rodrigues, Cláudia Matos, et al.
The Lancet. Oncology
|
September 19, 2014
Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data
Antonio Rossi, Paolo Chiodini, Jong-Mu Sun, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 22, 2010
Phase II, double-blinded, randomized study of enzastaurin plus pemetrexed as second-line therapy in patients with advanced non-small cell lung cancer
Alberto Chiappori, Gerold Bepler, Fabrice Barlesi, et al.
Page
of 2